PREVACID (lansoprazole) by Takeda is proton pump inhibitors [moa]. Approved for proton pump inhibitor [epc]. First approved in 1995.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
PREVACID (lansoprazole) is an oral proton pump inhibitor (PPI) approved in 1995 that reduces gastric acid secretion by inhibiting the H+/K+ ATPase pump in parietal cells. It is indicated for treatment of acid-reflux disorders, including GERD, peptic ulcer disease, and Zollinger-Ellison syndrome. The delayed-release capsule formulation allows targeted delivery to the small intestine for optimal absorption.
Mature product approaching loss of exclusivity with minimal remaining Part D utilization; brand team focus is on transition management and retention of residual market share.
Proton Pump Inhibitors
Proton Pump Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)
Worked on PREVACID at Takeda? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on PREVACID offers limited career growth due to its mature, declining lifecycle and approaching loss of exclusivity. Positions are primarily defensive and focused on managing legacy business and transitioning patients to newer Takeda products rather than driving innovation or market expansion.